Groupama Asset Managment Increases Holdings in Gilead Sciences, Inc. $GILD

Groupama Asset Managment increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 47.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,281 shares of the biopharmaceutical company’s stock after purchasing an additional 16,848 shares during the quarter. Groupama Asset Managment’s holdings in Gilead Sciences were worth $5,803,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the 3rd quarter worth $26,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences during the 2nd quarter worth $30,000. MTM Investment Management LLC grew its position in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares in the last quarter. Kilter Group LLC purchased a new position in shares of Gilead Sciences during the second quarter valued at $33,000. Finally, Millstone Evans Group LLC increased its stake in shares of Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares during the period. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Pipeline boost — Assembly Biosciences licensed a helicase‑primase inhibitor program (including candidates ABI‑5366 and ABI‑1179) to Gilead after positive Phase 1b interim data, adding early‑stage herpes assets to Gilead’s antiviral franchise and expanding near‑term development options. This is a clear pipeline + inorganic expansion signal. Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
• Positive Sentiment: Analyst support — Multiple firms have raised targets or maintain buy ratings (Deutsche Bank, Jefferies, BofA, Needham), lifting consensus target above the current trade and providing institutional buying ammunition. This helps underpin the shares despite short‑term weakness.
• Positive Sentiment: Shareholder return signal — Gilead recently raised its quarterly dividend to $0.82 (ann. $3.28), reinforcing cash‑flow confidence and appeal to income investors. Dividend / SEC Filing
• Neutral Sentiment: Trending attention / coverage — Zacks and other outlets flagged GILD as a trending stock; that can increase intraday volume and volatility but doesn’t indicate fundamental change. Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
• Neutral Sentiment: Market‑flow signals — Unusual options activity and recent coverage pieces on valuation have attracted attention; these can amplify swings but are ambiguous for direction until large trades or analyst revisions follow. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider selling — Recent disclosed sales (including Johanna Mercier and a reported sale by the CFO) have been highlighted in filings and press summaries; insider sales can weigh on sentiment even when they’re routine or pre‑planned. Insider Sale – Johanna Mercier CFO SEC Filing

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 309,280 shares of company stock worth $44,068,850. 0.27% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research reports. HSBC upped their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald raised their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Truist Financial boosted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Finally, Daiwa Securities Group lifted their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Price Performance

Shares of GILD stock opened at $141.11 on Friday. The stock’s 50-day moving average is $142.36 and its 200 day moving average is $127.60. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company has a market cap of $175.18 billion, a P/E ratio of 20.84, a PEG ratio of 1.85 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.